BioXcel Therapeutics Business Summary

BioXcel Therapeutics, Inc. (BTAI) is a commercial-stage biopharmaceutical company that generates revenue primarily through product sales of IGALMI (dexmedetomidine sublingual film), which is FDA-approved for the acute treatment of agitation associated with schizophrenia and bipolar disorder. The company operates through two primary business segments: Neuroscience, focused on expanding the IGALMI label for at-home use and dementia-related agitation (BXCL501), and Immuno-oncology, which develops BXCL701 for rare forms of prostate and pancreatic cancer. BioXcel utilizes its proprietary EvolverAI platform to re-innovate existing drugs, significantly reducing development timelines. In the competitive landscape, BTAI contends with established players like Intra-Cellular Therapies (Caplyta), Axsome Therapeutics (Auvelity), and Marinus Pharmaceuticals. As of early 2026, the company is positioned as a high-risk, high-reward micro-cap specialist attempting to pivot from institutional sales to the multi-billion dollar outpatient market following its January 2026 sNDA submission for at-home administration. Led by Co-Founder and CEO Vimal Mehta, Ph.D., who brings over two decades of experience from Sun Pharma and Invea Therapeutics, the executive team includes Senior VP and CFO Richard Steinhart, formerly of Remedy Pharmaceuticals, and Chief Scientific Officer Frank Yocca, Ph.D., an industry veteran with leadership pedigree from AstraZeneca and Bristol-Myers Squibb. The leadership is further bolstered by Interim Chief Commercial Officer Mark Pavao, who is spearheading the 2026 launch preparations for the at-home setting. The Board of Directors features prominent industry figures such as Chairman Peter Mueller, Ph.D. (former CSO of Vertex Pharmaceuticals), and newly appointed director Rajiv Patni, M.D. (CEO of Judo Bio and former R&D head at Reata Pharmaceuticals). Notable institutional backing includes the RSJ Life Sciences Fund and the company’s parent entity, BioXcel Corporation, which provided the foundational AI infrastructure and initial capital.